Article: High frequency of functional anti-YMDD and -mutant cytotoxic T lymphocytes after in vitro expansion correlates with successful response to lamivudine therapy for chronic hepatitis B

File Download Links for fulltext
(May Require Subscription)
Supplementary
  • Basic View
  • Metadata View
  • XML View
TitleHigh frequency of functional anti-YMDD and -mutant cytotoxic T lymphocytes after in vitro expansion correlates with successful response to lamivudine therapy for chronic hepatitis B
AuthorsLin, CL2
Tsai, SL3
Lee, TH1
Chien, RN1
Liao, SK1
Liaw, YF1
Issue Date2005
PublisherB M J Publishing Group. The Journal's web site is located at http://gut.bmjjournals.com/
CitationGut, 2005, v. 54 n. 1, p. 152-161 [How to Cite?]
DOI: http://dx.doi.org/10.1136/gut.2003.032920
AbstractBACKGROUND: Many determinants for a sustained response to lamivudine therapy have been reported but the role of T cell responsiveness remains unclear. The finding that tyrosine-methionine-aspartate-aspartate (YMDD) motif of the reverse transcriptase domain of hepatitis B virus (HBV) DNA polymerase carries a HLA-A2 restricted cytotoxic T lymphocyte (CTL) epitope makes quantitative measurement of the numbers of peptide specific CTLs feasible using MHC tetramer-peptide complex staining. AIM: To investigate the correlation between anti-YMDD motif CTL activity and the efficacy of lamivudine therapy in HLA-A2 positive patients with chronic hepatitis B (CH-B). METHODS: The function and phenotype of peptide and interleukin 2 expanded peripheral blood mononuclear cells were quantified by cell lytic assay and immunocytochemical analysis by staining with HLA-A2-peptide tetramer complexes. RESULTS: After in vitro expansion, sustained responders had more potent CTL responses against YMDD, YVDD, and YIDD, as well as other epitopes on HBV antigens than non-responders. The frequency of YMDD/YVDD/YIDD motif specific CTLs increased significantly with an effective cell lytic function during and after therapy in sustained responders but not in non-responders. YMDD specific CTLs cross reacted with YIDD and YVDD mutant epitopes, and shared T cell receptor gene usages with YIDD and YVDD specific CTLs. CONCLUSIONS: Sustained responders, at least HLA-A2 patients, elicited a more potent CTL immunity against YMDD and its mutants. YMDD specific CTLs are cross reactive with YVDD and YIDD mutant epitopes, which may further contribute to immune clearance of the mutant viruses and a successful response to lamivudine therapy in CH-B patients.
ISSN0017-5749
2011 Impact Factor: 10.111
2011 SCImago Journal Rankings: 0.883
DOIhttp://dx.doi.org/10.1136/gut.2003.032920
ISI Accession Number IDWOS:000225659500028
PubMed Central IDPMC1774356
DC Field
Value
dc.contributor.authorLin, CL
dc.contributor.authorTsai, SL
dc.contributor.authorLee, TH
dc.contributor.authorChien, RN
dc.contributor.authorLiao, SK
dc.contributor.authorLiaw, YF
dc.date.accessioned2007-10-30T06:24:02Z
dc.date.available2007-10-30T06:24:02Z
dc.date.issued2005
dc.description.abstractBACKGROUND: Many determinants for a sustained response to lamivudine therapy have been reported but the role of T cell responsiveness remains unclear. The finding that tyrosine-methionine-aspartate-aspartate (YMDD) motif of the reverse transcriptase domain of hepatitis B virus (HBV) DNA polymerase carries a HLA-A2 restricted cytotoxic T lymphocyte (CTL) epitope makes quantitative measurement of the numbers of peptide specific CTLs feasible using MHC tetramer-peptide complex staining. AIM: To investigate the correlation between anti-YMDD motif CTL activity and the efficacy of lamivudine therapy in HLA-A2 positive patients with chronic hepatitis B (CH-B). METHODS: The function and phenotype of peptide and interleukin 2 expanded peripheral blood mononuclear cells were quantified by cell lytic assay and immunocytochemical analysis by staining with HLA-A2-peptide tetramer complexes. RESULTS: After in vitro expansion, sustained responders had more potent CTL responses against YMDD, YVDD, and YIDD, as well as other epitopes on HBV antigens than non-responders. The frequency of YMDD/YVDD/YIDD motif specific CTLs increased significantly with an effective cell lytic function during and after therapy in sustained responders but not in non-responders. YMDD specific CTLs cross reacted with YIDD and YVDD mutant epitopes, and shared T cell receptor gene usages with YIDD and YVDD specific CTLs. CONCLUSIONS: Sustained responders, at least HLA-A2 patients, elicited a more potent CTL immunity against YMDD and its mutants. YMDD specific CTLs are cross reactive with YVDD and YIDD mutant epitopes, which may further contribute to immune clearance of the mutant viruses and a successful response to lamivudine therapy in CH-B patients.
dc.description.naturepublished_or_final_version
dc.format.extent410099 bytes
dc.format.extent476510 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypeapplication/pdf
dc.identifier.citationGut, 2005, v. 54 n. 1, p. 152-161 [How to Cite?]
DOI: http://dx.doi.org/10.1136/gut.2003.032920
dc.identifier.doihttp://dx.doi.org/10.1136/gut.2003.032920
dc.identifier.isiWOS:000225659500028
dc.identifier.issn0017-5749
2011 Impact Factor: 10.111
2011 SCImago Journal Rankings: 0.883
dc.identifier.openurl
dc.identifier.pmcidPMC1774356
dc.identifier.pmid15591521
dc.identifier.scopuseid_2-s2.0-10844242136
dc.identifier.urihttp://hdl.handle.net/10722/45372
dc.languageeng
dc.publisherB M J Publishing Group. The Journal's web site is located at http://gut.bmjjournals.com/
dc.rightsGut. Copyright © B M J Publishing Group.
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License
dc.subject.meshHepatitis-B,-Chronic-drug-therapy
dc.subject.meshLamivudine-therapeutic-use
dc.subject.meshReverse-Transcriptase-Inhibitors-therapeutic-use
dc.subject.meshT-Lymphocytes,-Cytotoxic-immunology
dc.titleHigh frequency of functional anti-YMDD and -mutant cytotoxic T lymphocytes after in vitro expansion correlates with successful response to lamivudine therapy for chronic hepatitis B
dc.typeArticle
Author Affiliations
  1. Chang Gung University College of Medicine
  2. The University of Hong Kong
  3. null